ResMed Inc.
Company & revenue
About ResMed Inc.
Financial breakdown: year ended 2026-06-30
Who they are
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices.
Product / operating segments
Reported percentage. Percentages use consolidated company revenue unless a different denominator is stated.
Geographic revenuePREMIUM
Reported percentage. Percentages use consolidated company revenue unless a different denominator is stated.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
59
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
86
Strong
Financial Strength
93
Business Quality / Moat
94
Management
100
Growth Quality
33
Risk / Durability
94
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
61
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
61/100
Building Historical Record
Model Score 61/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as mixed to moderately strong.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for RMD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can RMD maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is RMD's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is RMD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
Essential Investment Snapshot
Wall Street Score
59
Opportunity Score
61
Market Cap
$31.75B
P/E Ratio
21.3
EPS
$10.44
52-Week High
$284.87
52-Week Low
$180.27
Beta
0.77
Intrinsic Value
$301.98
Analyst Target
$230.00
Shares Outstanding
145.0M
Total Debt
$825.9M
Dividend Yield
1.08%
Liquidation Value / Share
$45.42
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for RMD
Detected from reported data — verify before acting.Dividend history reported
The provider reports a dividend yield. Confirm the latest declaration before treating it as a current payment.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on RMD.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and per.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
UndervaluedCurrent Price
$218.89
Intrinsic Value
$301.98
Difference
−$83.09
-27.5% vs IV
Margin of Safety
27.5%
Related Companies
Medical - Instruments & SuppliesNews
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial